VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase and into the next stage of development. This milestone is part of the company's broader efforts to build a diversified oncology pipeline and expand its intellectual property portfolio.
The VXA-222 program, which is not based on VERAXA's proprietary BiTAC platform, leverages the company's antibody engineering, linker, and conjugation technologies. The program has successfully completed the discovery phase in collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). With the discovery work completed, VERAXA will now focus on engineering the final bispecific antibody-drug conjugate candidate and advancing preclinical validation.
In addition to the development progress, VERAXA has recently expanded its intellectual property portfolio with its first BiTAC-related patent filings, alongside additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047.
This expansion of intellectual property is crucial for VERAXA as it builds a diversified oncology pipeline spanning bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers. The company's focus on next-generation antibody technologies positions it to potentially address significant unmet medical needs in oncology.
The advancement of VXA-222 and the strengthening of its patent portfolio are important steps for VERAXA as it seeks to establish itself as a key player in the development of novel cancer therapies. The company's continued progress reflects its commitment to innovation and its strategic approach to building a robust pipeline.
For more information on VERAXA and its pipeline, visit the company's newsroom at https://ibn.fm/VRXA.
